Phase 4 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have chronic hepatitis B and have been taking one of these antiviral medications (entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) on its own for at least 12 months
- You have been diagnosed with type 2 diabetes, or have blood sugar levels high enough to suggest diabetes or pre-diabetes (based on specific blood sugar or HbA1c test results — confirm with trial site)
- You have been on the same diabetes medication(s) for the past three months without any changes
- You have advanced liver scarring or signs of increased pressure in the liver's blood vessels, confirmed by specific scan or ultrasound measurements, or visible signs such as an enlarged spleen, fluid in the abdomen, or enlarged veins (confirm with trial site)
- You are 18 years old or older
- You are willing and able to give written consent to take part
Who may not be able to join:
- You have hepatitis C, shown by a positive blood test for the hepatitis C virus
- You have had serious complications from liver cirrhosis, or have been diagnosed with liver cancer
- You have had an organ transplant
- You are already taking a type of diabetes medication called an SGLT2 inhibitor (confirm with trial site for specific drug names)
- Your kidneys are not working well enough (kidney filtration rate below a certain level — confirm with trial site)
- Your blood sugar control is very poor, with an HbA1c level above 9.0%
- You are taking three or more different diabetes medications
- Your diabetes medications have been changed in the last three months
- You have a serious illness or any form of cancer
- You are under 18 years old
- You are not willing or able to give consent to take part
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Grace LH Wong, MD, Chinese University of Hong Kong
Phone: +85235054205
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint is liver complications
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.